Secuenciación en cáncer de mama avanzado HER2+ - page 44

496 471 453 435 403 368 297 240 204 159 133 110
86 63 45
27
17
7
4
495 485 474 457 439 418 349 293 242 197 164 136 111 86 62
38
28
13
5
Cap + Lap
T-DM1
No. at risk:
Time (months)
78.4%
64.7%
51.8%
85.2%
0
2
4 6
8 10 12 14 16 18 20 22 24 26 28 30 32 34 36
0.0
0.2
0.4
0.6
0.8
1.0
Proportion surviving
Median (months) No. of events
Cap + Lap
25.1
182
T-DM1
30.9
149
Stratified HR=0.682 (95% CI, 0.55, 0.85);
P
=0.0006
Efficacy stopping boundary P=0.0037 or HR=0.727
Verma S, NEJM 2012
EMILIA: Overall Survival
1...,34,35,36,37,38,39,40,41,42,43 45,46,47,48,49,50,51,52,53,54,...60
Powered by FlippingBook